Literature DB >> 7173866

Somatic cell hybridization studies on the genetic regulation and allelic mutations in metachromatic leukodystrophy.

P L Chang, N E Rosa, R G Davidson.   

Abstract

Metachromatic leukodystrophy is a hereditary neurodegenerative disease associated with deficient arylsulfatase A activity. Clinical variants differ in onset times and severity of the disease but each breeds true within families. Somatic cell hybridization techniques were used to clarify the genetic relationship among these mutants. Hybrid clones isolated with a nonselective method from fusing fibroblasts of an infantile and a juvenile variant did not show complementation of arylsulfatase A activity. Hence, these clinical variants are allelic mutants. Previous somatic cell hybridization studies suggested that "arylsulfatase A-deficiency" is a dominant phenotype, in contrast to its apparent recessive mode of inheritance. To resolve this discrepancy, hybrid clones from fusing normal and arylsulfatase A-deficient fibroblasts were isolated nonselectively. They continued to express arylsulfatase A activity. Hence, even in vitro, "arylsulfatase A-deficiency" remains as a recessive phenotype.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173866     DOI: 10.1007/bf00296448

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  22 in total

1.  Purification and some properties of soluble human liver arylsulfatases.

Authors:  E Shapira; H L Nadler
Journal:  Arch Biochem Biophys       Date:  1975-09       Impact factor: 4.013

Review 2.  Studies in metachromatic leukodystrophy XI. Therapeutic considerations, 1972.

Authors:  J H Austin
Journal:  Birth Defects Orig Artic Ser       Date:  1973-03

3.  Regulation in man times man somatic cell hybrids: possible negative control of arylsulphatase A.

Authors:  M C Hors-Cayla; S Heuertz; J Y Picard; J Frézal
Journal:  Ann Hum Genet       Date:  1974-07       Impact factor: 1.670

4.  A correlation of intracellular cerebroside sulfatase activity in fibroblasts with latency in metachromatic leukodystrophy.

Authors:  M T Porter; A L Fluharty; J Trammell; H Kihara
Journal:  Biochem Biophys Res Commun       Date:  1971-08-06       Impact factor: 3.575

5.  Cerebroside-sulphatase and arylsulphatase A deficiency in metachromatic leukodystrophy (ML).

Authors:  H Jatzkewitz; E Mehl
Journal:  J Neurochem       Date:  1969-01       Impact factor: 5.372

6.  Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol.

Authors:  R L Davidson; P S Gerald
Journal:  Somatic Cell Genet       Date:  1976-03

7.  Purification and properties of arylsulfatase. A from human urine.

Authors:  R L Stevens; A L Fluharty; M H Skokut; H Kihara
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

8.  Metachromatic leukodystrophy (MLD). 8. MLD in adults; diagnosis and pathogenesis.

Authors:  J Austin; D Armstrong; S Fouch; C Mitchell; D Stumpf; L Shearer; O Briner
Journal:  Arch Neurol       Date:  1968-03

9.  Adult metachromatic leukodystrophy. III. Clinical course, final stages and first biochemical results.

Authors:  D Seidel; R Heipertz; H H Goebel; I Duensing; H Pilz
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

10.  Complementation of arylsulfatase A in somatic hybrids of metachromatic leukodystrophy and multiple sulfatase deficiency disorder fibroblasts.

Authors:  P L Chang; R G Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

View more
  2 in total

1.  The human arylsulfatase-C isoenzymes: two distinct genes that escape from X inactivation.

Authors:  P L Chang; O T Mueller; R M Lafrenie; P A Varey; N E Rosa; R G Davidson; W M Henry; T B Shows
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

2.  Pseudo arylsulfatase-A deficiency in healthy individuals: genetic and biochemical relationship to metachromatic leukodystrophy.

Authors:  P L Chang; R G Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.